Evaluation of Compounds That Prevent Reactivation of HIV-1 in OM-10.1 Cells

It is critically important that new therapeutic compounds and targets for therapeutic intervention be identified in the battle against the human immunodeficieny virus type 1(HIV-1). Many of the currently existing therapeutic approaches target virus-specific factors involved in steps along the HIV-1 life cycle prior to proviral integration. These preintegrative or afferent therapeutic approaches initially appeared quite promising (like reverse transcriptase [RT] inhibitors and soluble CD4) but have shown disappointing clinical benefit. With the recent appreciation of suppression of HIV-1 fusion by selected chemokines, more development of afferent inhibitors is certainly on the horizon.